{"id":"multi-dose-antibiotic","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Hypersensitivity reaction"},{"rate":null,"effect":"Photosensitivity"}]},"_chembl":{"chemblId":"CHEMBL606111","moleculeType":"Small molecule","molecularWeight":"1040.49"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a marketed antibiotic product from Cleveland Clinic that combines multiple antibiotic agents in a single dosing regimen. The specific mechanism depends on the constituent antibiotics, which typically work by inhibiting bacterial cell wall synthesis, protein synthesis, or nucleic acid replication. Multi-dose formulations are designed to optimize pharmacokinetics and improve patient compliance.","oneSentence":"A multi-dose antibiotic formulation that delivers multiple antimicrobial agents to treat bacterial infections.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:56:02.146Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections (specific indications unknown)"}]},"trialDetails":[{"nctId":"NCT06748144","phase":"PHASE2, PHASE3","title":"IO Vancomycin Spine","status":"NOT_YET_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2026-05","conditions":"Lumbar Fusion Surgery","enrollment":30},{"nctId":"NCT05184764","phase":"PHASE1, PHASE2","title":"Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia","status":"COMPLETED","sponsor":"Armata Pharmaceuticals, Inc.","startDate":"2022-04-26","conditions":"Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia","enrollment":56},{"nctId":"NCT06462235","phase":"PHASE2","title":"A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-09-25","conditions":"Gram-negative Bacterial Infection","enrollment":48},{"nctId":"NCT07485010","phase":"PHASE2","title":"Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial","status":"NOT_YET_RECRUITING","sponsor":"The University of Queensland","startDate":"2027-04","conditions":"Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Infections","enrollment":300},{"nctId":"NCT06911424","phase":"PHASE3","title":"Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis","status":"RECRUITING","sponsor":"Baxis Pharmaceuticals, Inc.","startDate":"2025-03-21","conditions":"Bacterial Conjunctivitis","enrollment":400},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT06214403","phase":"PHASE2","title":"Antimicrobial Resistant Organism Decolonization After Microbiome Perturbation","status":"WITHDRAWN","sponsor":"University Health Network, Toronto","startDate":"2026-07","conditions":"Gram-negative Bacteremia, Microbial Colonization, Antibiotic Resistant Infection","enrollment":""},{"nctId":"NCT06488781","phase":"PHASE2","title":"Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term 2.0","status":"RECRUITING","sponsor":"University of Oklahoma","startDate":"2025-04-29","conditions":"Obesity in Pregnancy, Labor Complication","enrollment":787},{"nctId":"NCT06086626","phase":"PHASE2","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants","status":"COMPLETED","sponsor":"Shionogi","startDate":"2024-03-14","conditions":"Gram-Negative Bacterial Infections","enrollment":30},{"nctId":"NCT04335539","phase":"PHASE2","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric Participants","status":"COMPLETED","sponsor":"Shionogi","startDate":"2020-08-21","conditions":"Gram-negative Bacterial Infections, Bloodstream Infections (BSI), Complicated Intra-abdominal Infection (cIAI)","enrollment":53},{"nctId":"NCT06528496","phase":"PHASE2","title":"N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-07-22","conditions":"High-risk Neuroblastoma, Neuroblastoma, Childhood Neuroblastoma","enrollment":45},{"nctId":"NCT03594487","phase":"PHASE1","title":"Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis","status":"TERMINATED","sponsor":"Jeffrey Gelfand","startDate":"2018-11-16","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":5},{"nctId":"NCT04986254","phase":"","title":"PNEUmonia DOSing in Critically Ill Patients (PNEUDOS)","status":"COMPLETED","sponsor":"The University of Queensland","startDate":"2019-10-17","conditions":"Pneumonia","enrollment":179},{"nctId":"NCT06229288","phase":"PHASE3","title":"Amoxicillin Alone Versus Amoxicillin/Clavulanate for Community-acquired Pneumonia in Patients Aged 65 Years or Older, and Hospitalized in a Non-intensive Care Unit Ward","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-04-25","conditions":"Community-acquired Pneumonia","enrollment":326},{"nctId":"NCT03283878","phase":"PHASE4","title":"Antibiotic Prophylaxis in Patients Undergoing Elective Total Knee Arthroplasty- Multi-center Trial","status":"COMPLETED","sponsor":"Duke University","startDate":"2017-10-24","conditions":"Arthropathy of Knee, Antibiotic Prophylaxis","enrollment":1770},{"nctId":"NCT05753215","phase":"PHASE2","title":"Controlled Trial of Omadacycline Randomized Treatment Given for Bone and Joint Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2023-05-09","conditions":"Bone Infection, Joint Infection, Bone and Joint Infection","enrollment":180},{"nctId":"NCT06692452","phase":"PHASE2","title":"Tazemetostat Plus CHOP in 1L T-cell Lymphoma","status":"SUSPENDED","sponsor":"Eric Jacobsen, MD","startDate":"2024-12-24","conditions":"Lymphoma, Peripheral T Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma","enrollment":24},{"nctId":"NCT07280598","phase":"PHASE1","title":"Safety of Combined Intravenous Antibiotic and Bacteriophage Therapy in Adults With Cystic Fibrosis and Antibiotic-Resistant Lung Infections","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Diego","startDate":"2025-12-31","conditions":"CF - Cystic Fibrosis, Klebsiella Pneumoniae Infection, E Coli Infections","enrollment":30},{"nctId":"NCT04877379","phase":"PHASE1","title":"VNRX-7145 Drug-Drug Interaction in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Basilea Pharmaceutica","startDate":"2021-06-08","conditions":"Healthy Subjects","enrollment":53},{"nctId":"NCT02570542","phase":"PHASE2","title":"Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2015-10","conditions":"Diffuse Large B-cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Refractory Diffuse Large B-cell Lymphoma (DLBCL)","enrollment":59},{"nctId":"NCT01543334","phase":"","title":"Antibiotic Concentrations Among Critically Ill Patients","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2012-03","conditions":"Administration of Antibiotics in Intensive Care Units","enrollment":98},{"nctId":"NCT07227584","phase":"PHASE2","title":"ALL Backbone in AYAs","status":"NOT_YET_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2026-04","conditions":"Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Negative Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL)","enrollment":67},{"nctId":"NCT06321536","phase":"PHASE2","title":"Response to Emerging Antimicrobial Resistance With Containment Microbiota Therapy (REACT)","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-01-13","conditions":"Multi-Drug Resistant Organism Colonization","enrollment":60},{"nctId":"NCT07207434","phase":"PHASE2","title":"Maternal Probiotic Intervention to Improve Gut Health-Trial II-Pakistan","status":"RECRUITING","sponsor":"Aga Khan University","startDate":"2025-08-30","conditions":"Environmental Enteric Dysfunction (EED), Stunting","enrollment":144},{"nctId":"NCT07184840","phase":"PHASE2","title":"Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder","status":"RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2025-09-09","conditions":"Neuromyelitis Optica Spectrum Disorder Attack","enrollment":110},{"nctId":"NCT06673394","phase":"PHASE2","title":"Eculizumab For Acute Attack of Neuromyelitis Optica Spectrum Disorder","status":"WITHDRAWN","sponsor":"Tianjin Medical University General Hospital","startDate":"2025-09-03","conditions":"Neuromyelitis Optica Spectrum Disorder Attack","enrollment":""},{"nctId":"NCT00814905","phase":"NA","title":"Treatment of Chorioamnionitis After Delivery","status":"WITHDRAWN","sponsor":"United States Naval Medical Center, Portsmouth","startDate":"2008-11-18","conditions":"Chorioamnionitis","enrollment":""},{"nctId":"NCT07053943","phase":"","title":"Infection-related Revision Rates After Single-dose Versus Multiple-dose Antibiotic Prophylaxis in Primary Hip and Knee Arthroplasty: a Comparative Implementation Study.","status":"ENROLLING_BY_INVITATION","sponsor":"JointResearch","startDate":"2025-06-01","conditions":"Total Hip Arthroplasty (THA), Antibiotic Prophylaxis, Revision Arthroplasty","enrollment":70000},{"nctId":"NCT05835206","phase":"PHASE2","title":"Further MT for Antibiotic-Resistant Bacterial Colonization in Inpatients","status":"RECRUITING","sponsor":"Emory University","startDate":"2024-04-25","conditions":"Multi-drug Resistant Organism","enrollment":40},{"nctId":"NCT06189638","phase":"PHASE2","title":"Phase II Study to Evaluate Efficacy and Safety of AMP Peptide PL-5 in Mild Infections of Diabetic Foot Ulcers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.","startDate":"2024-01-30","conditions":"Diabetic Foot Ulcers","enrollment":90},{"nctId":"NCT03931447","phase":"PHASE1","title":"A Safety and Tolerability Study of JNJ-72537634 in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-04-30","conditions":"Healthy","enrollment":31},{"nctId":"NCT06170372","phase":"NA","title":"High-dose Inhalations of Nitric Oxide in the Treatment of Pneumonia","status":"RECRUITING","sponsor":"Tomsk National Research Medical Center of the Russian Academy of Sciences","startDate":"2024-01-15","conditions":"Nosocomial Pneumonia, Community-acquired Pneumonia","enrollment":200},{"nctId":"NCT05845073","phase":"NA","title":"The Efficacy of a Probiotic for Antibiotic Associated Gastrointestinal Symptoms","status":"COMPLETED","sponsor":"The Archer-Daniels-Midland Company","startDate":"2023-05-09","conditions":"Antibiotic-associated Diarrhea","enrollment":69},{"nctId":"NCT05427136","phase":"","title":"Early Pulmonary Dysfunction in Childhood Cancer Patients","status":"RECRUITING","sponsor":"University Children's Hospital Basel","startDate":"2021-06-01","conditions":"Pulmonary Dysfunction","enrollment":140},{"nctId":"NCT06893835","phase":"PHASE4","title":"Comparative Study of Clinical Outcomes and Safety Between Colistin and Tigecycline","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beni-Suef University","startDate":"2024-12-01","conditions":"Infection in ICU","enrollment":132},{"nctId":"NCT05530174","phase":"NA","title":"Effect of Single vs Multiple Prophylactic Antibiotic Doses on PJI Following Primary THA in Patients With a Fracture","status":"ACTIVE_NOT_RECRUITING","sponsor":"Soren Overgaard","startDate":"2022-09-01","conditions":"Fracture of Hip, Total Hip Arthroplasty, Prosthetic-joint Infection","enrollment":2000},{"nctId":"NCT05530551","phase":"NA","title":"Effect of Single vs Multiple Prophylactic Antibiotic Doses on PJI Following Primary THA in Patients With OA","status":"ACTIVE_NOT_RECRUITING","sponsor":"Soren Overgaard","startDate":"2022-09-01","conditions":"Osteoarthritis, Hip, Total Hip Arthroplasty, Prosthetic-joint Infection","enrollment":20000},{"nctId":"NCT06841211","phase":"NA","title":"Optimizing Prostate Biopsy Schemes in Men With Multiple mpMRI Visible Lesions","status":"RECRUITING","sponsor":"Peking University First Hospital","startDate":"2025-02-01","conditions":"Prostate Cancer","enrollment":400},{"nctId":"NCT06760065","phase":"PHASE3","title":"Comparison of Keverprazan Hydrochloride-Amoxicillin Dual Therapy and Susceptibility-Guided Quadruple Therapy for Helicobacter Pylori Rescue Treatment","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2025-01-15","conditions":"Helicobacter Pylori Infection Helicobacter Pylori Eradication Patient Education","enrollment":316},{"nctId":"NCT06055777","phase":"PHASE1","title":"Study of the Safety, Tolerability, and PK of SZEY-2108 Administered Intravenously to HVs in SAD and MAD Cohorts","status":"TERMINATED","sponsor":"Suzhou Erye Pharmaceutical Co., Ltd.","startDate":"2023-09-07","conditions":"Infections","enrollment":64},{"nctId":"NCT06015165","phase":"NA","title":"Outcomes for Anesthesiologist-Led Care of Analgesic Protocol in Anorectal Surgery","status":"RECRUITING","sponsor":"China-Japan Friendship Hospital","startDate":"2024-09-10","conditions":"Postoperative Pain","enrollment":216},{"nctId":"NCT05174806","phase":"PHASE2","title":"Multi-center Study to Assess Safety, Tolerability and Efficacy of Topical Pravibismane in Moderate DFI Patients","status":"COMPLETED","sponsor":"Microbion Corporation","startDate":"2022-06-13","conditions":"Diabetic Foot Infection, Diabetic Foot","enrollment":47},{"nctId":"NCT04769895","phase":"PHASE3","title":"MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"MaaT Pharma","startDate":"2022-03-25","conditions":"Acute Graft Versus Host Disease in Intestine, Steroid Refractory GVHD","enrollment":66},{"nctId":"NCT06569342","phase":"","title":"Botulinum Neurotoxin Type A (BoNT-A) in Paediatric Non-neurogenic Therapy Resistant Overactive Bladder (OAB)","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2022-01-15","conditions":"Overactive Bladder, Incontinence, Daytime Urinary, Incontinence, Nighttime Urinary","enrollment":43},{"nctId":"NCT04998513","phase":"NA","title":"Medical Versus Surgical Treatment for Peritonsillar Abscesses","status":"WITHDRAWN","sponsor":"Nova Scotia Health Authority","startDate":"2022-01","conditions":"Peritonsillar Abscess, Surgical Incision","enrollment":""},{"nctId":"NCT06527989","phase":"PHASE2, PHASE3","title":"Prophylactic Antibiotic in Subtalar Fusion Surgery","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-09-01","conditions":"Surgical Site Infection","enrollment":102},{"nctId":"NCT05709028","phase":"PHASE3","title":"Fosfomycin Versus Standard of Care in Children With Antibiotic-resistant Urinary Tract Infections","status":"RECRUITING","sponsor":"University of Sydney","startDate":"2023-08-02","conditions":"Urinary Tract Infections","enrollment":300},{"nctId":"NCT04631185","phase":"NA","title":"Surgical Site Infection and Antibiotic Use Study","status":"COMPLETED","sponsor":"The Plastic Surgery Foundation","startDate":"2021-05-07","conditions":"Surgical Site Infection, Breast Reconstruction, Antibiotic Use","enrollment":235},{"nctId":"NCT04625907","phase":"PHASE1, PHASE2","title":"FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2020-09-17","conditions":"Rhabdomyosarcoma","enrollment":1672},{"nctId":"NCT06402591","phase":"PHASE3","title":"Results of Extended Versus Single Dose Antibiotic Prophylaxis In Orthopedic Revision Arthroplasty in Nijmegen.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2019-01-01","conditions":"Infection Prosthesis Hip and Knee, Infection, Prosthesis Related, Joint Infection","enrollment":751},{"nctId":"NCT05709184","phase":"NA","title":"Lyophilized Fecal Microbiome Transfer vs. Vancomycin Monotherapy for Primary Clostridioides Difficile Infection","status":"RECRUITING","sponsor":"Rambam Health Care Campus","startDate":"2023-11-15","conditions":"Clostridioides Difficile Infection","enrollment":196},{"nctId":"NCT04126031","phase":"PHASE2","title":"Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants.","status":"TERMINATED","sponsor":"Pfizer","startDate":"2020-01-14","conditions":"Gram-negative Bacterial Infection","enrollment":48},{"nctId":"NCT04532957","phase":"PHASE1","title":"A Multiple Ascending Dose Study to Investigate Safety of KBP-7072 in Healthy Subjects","status":"COMPLETED","sponsor":"KBP Biosciences","startDate":"2020-08-11","conditions":"Healthy","enrollment":24},{"nctId":"NCT05276401","phase":"PHASE2","title":"Nu-3 Topical Gel for Treatment of Diabetic Foot Ulcer","status":"TERMINATED","sponsor":"Lakewood-Amedex Inc","startDate":"2022-03-11","conditions":"Chronic Diabetic Foot Ulcers","enrollment":3},{"nctId":"NCT05719285","phase":"PHASE4","title":"Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2022-12-06","conditions":"Overactive Bladder, Overactive Bladder Syndrome, Urge Incontinence","enrollment":100},{"nctId":"NCT05926466","phase":"PHASE2","title":"BTZ-043 Dose Evaluation in Combination and Selection","status":"UNKNOWN","sponsor":"Michael Hoelscher","startDate":"2023-09-21","conditions":"Tuberculosis, Pulmonary, Other Specified Pulmonary Tuberculosis","enrollment":90},{"nctId":"NCT05340790","phase":"PHASE1","title":"First in Human Study in Healthy Volunteers of Antimicrobial Peptide PL-18 Vaginal Suppositories","status":"UNKNOWN","sponsor":"Protelight Pharmaceuticals Australia PTY LTD","startDate":"2022-08-01","conditions":"Colpomycosis, Bacterial Vaginosis, Mixede Vaginitis","enrollment":50},{"nctId":"NCT05613361","phase":"PHASE3","title":"The Effect of Curcumin Against Colistin-induced Nephrotoxicity","status":"UNKNOWN","sponsor":"October 6 University","startDate":"2023-01-01","conditions":"Acute Kidney Injury, Drug-Induced Nephropathy","enrollment":214},{"nctId":"NCT01849874","phase":"PHASE3","title":"A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer","status":"TERMINATED","sponsor":"Pfizer","startDate":"2013-06-27","conditions":"Low-grade Serous Ovarian Cancer, Low-grade Serous Fallopian Tube Cancer, Low-grade Serous Peritoneal Cancer","enrollment":341},{"nctId":"NCT05974657","phase":"NA","title":"Effectiveness and Safety of Lactobacillus Acidophilus LA85 in Preventing Antibiotic-Associated Diarrhea","status":"COMPLETED","sponsor":"Wecare Probiotics Co., Ltd.","startDate":"2021-08-31","conditions":"Antibiotic Side Effect, Probiotics, Diarrhea","enrollment":82},{"nctId":"NCT03341273","phase":"NA","title":"Placebo-Controlled Trial of Antibiotic Therapy in Adults With Suspect Lower Respiratory Tract Infection (LRTI) and a Procalcitonin Level","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-12-08","conditions":"Lower Respiratory Tract Infection","enrollment":514},{"nctId":"NCT00621192","phase":"PHASE1, PHASE2","title":"Pharmacokinetic (PK) and Safety Study of Meropenem in Young Infants With Intra-abdominal Infections","status":"COMPLETED","sponsor":"The Emmes Company, LLC","startDate":"2008-06","conditions":"Necrotizing Enterocolitis, Intra-abdominal Infection","enrollment":200},{"nctId":"NCT01478035","phase":"PHASE4","title":"Study on the Efficacy of Phenytoin in the Prophylaxis of Seizures of Patients With Pneumococcal Meningitis at Least 50 Yrs Old.","status":"TERMINATED","sponsor":"M. Carmen Cabellos Minguez","startDate":"2011-11","conditions":"Seizures, Pneumococcal Meningitis","enrollment":26},{"nctId":"NCT05710094","phase":"PHASE1","title":"Safety and Tolerability of Single and Multiple Doses of SoftOx Biofilm Eradicator (SBE) in Chronic Leg Wounds","status":"COMPLETED","sponsor":"SoftOx Solutions AS","startDate":"2021-10-19","conditions":"Chronic Leg Ulcer, Venous Leg Ulcer","enrollment":28},{"nctId":"NCT03962725","phase":"PHASE4","title":"Avoiding Neuromuscular Blockers to Reduce Complications","status":"TERMINATED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2019-08-07","conditions":"Respiratory Failure, Respiratory Infection, Aspiration Pneumonia","enrollment":3},{"nctId":"NCT05702762","phase":"PHASE2","title":"Single Dose Aminoglycosides for Acute Uncomplicated Cystitis in the Emergency Department Setting","status":"UNKNOWN","sponsor":"Mercy Health Ohio","startDate":"2022-10-01","conditions":"Urinary Tract Infections","enrollment":160},{"nctId":"NCT03004365","phase":"PHASE2","title":"A Study to Evaluate the Safety and Microbiology of C16G2 Varnish Administered in Multiple Doses to Dental Subjects","status":"COMPLETED","sponsor":"Armata Pharmaceuticals, Inc.","startDate":"2017-01-27","conditions":"Dental Caries","enrollment":33},{"nctId":"NCT03052842","phase":"PHASE2","title":"A Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Dental Strip Application","status":"COMPLETED","sponsor":"Armata Pharmaceuticals, Inc.","startDate":"2017-02-09","conditions":"Dental Caries","enrollment":30},{"nctId":"NCT03196219","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Varnish and Strip in Adolescent and Adult Subjects","status":"COMPLETED","sponsor":"Armata Pharmaceuticals, Inc.","startDate":"2017-07-07","conditions":"Dental Caries","enrollment":20},{"nctId":"NCT05393505","phase":"PHASE4","title":"Fast-track Blood Test for Suspected Fever by Deficiency of a Kind of White Blood Cells As Main Defense Against Infection","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2022-10-24","conditions":"Neutropenic Fever","enrollment":344},{"nctId":"NCT05597553","phase":"NA","title":"Evaluation of Premixed Verses Powder/Liquid Bioceramic MTA in Indirect Pulp Capping.","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2023-01-01","conditions":"Indirect Pulp Capping","enrollment":24},{"nctId":"NCT04808414","phase":"PHASE1","title":"SAD/MAD Safety and PK Study of QPX9003 (Novel Polymyxin) in Normal Healthy Volunteers","status":"COMPLETED","sponsor":"Qpex Biopharma, Inc.","startDate":"2021-06-03","conditions":"Bacterial Infections","enrollment":104},{"nctId":"NCT03939429","phase":"PHASE1","title":"Phase 1 Study of Oral QPX2015 in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Qpex Biopharma, Inc.","startDate":"2019-05-20","conditions":"Bacterial Infections","enrollment":40},{"nctId":"NCT04380207","phase":"PHASE1","title":"P1 Single and Multiple Ascending Dose (SAD/MAD) Study of IV QPX7728 Alone and Combined With QPX2014 in NHV","status":"COMPLETED","sponsor":"Qpex Biopharma, Inc.","startDate":"2020-11-24","conditions":"Bacterial Infections","enrollment":82},{"nctId":"NCT03619252","phase":"PHASE4","title":"Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents","status":"COMPLETED","sponsor":"Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology","startDate":"2018-07-01","conditions":"Multiple Myeloma, Pneumococcal Infection, Febrile Neutropenia","enrollment":36},{"nctId":"NCT04382651","phase":"PHASE2","title":"Study of Efficacy and Safety of MAS825 in Patients With COVID-19","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-06-11","conditions":"COVID-19 Pneumonia, Impaired Respiratory Function","enrollment":140},{"nctId":"NCT05329168","phase":"PHASE2","title":"ERAdicate S. Aureus in Patients With Bacteremia and Endocarditis","status":"WITHDRAWN","sponsor":"Lysovant","startDate":"2022-05-01","conditions":"Bacteremia Due to Staphylococcus Aureus, Left Sided Infective Endocarditis (Disorder), Right Sided Infective Endocarditis (Disorder)","enrollment":""},{"nctId":"NCT02607449","phase":"PHASE3","title":"FS-1 Drug for Treatment of Multiple Drug-resistant Tuberculosis","status":"COMPLETED","sponsor":"Scientific Center for Anti-infectious Drugs, Kazakhstan","startDate":"2013-12","conditions":"Tuberculosis, MDR","enrollment":344},{"nctId":"NCT03474276","phase":"PHASE3","title":"Comparing Several Strategies to Manage Moderate Acute Malnutrition Among Children From 6 to 24 Months Old","status":"COMPLETED","sponsor":"Institut Pasteur","startDate":"2018-01-31","conditions":"Moderate Acute Malnutrition","enrollment":1357},{"nctId":"NCT05348239","phase":"PHASE2","title":"Chlorophyllin Tablets for Urinary Bleeding Following Radiation Therapy for Cancers of Pelvic Organs","status":"UNKNOWN","sponsor":"Tata Memorial Centre","startDate":"2022-03-26","conditions":"Hemorrhagic Cystitis","enrollment":24},{"nctId":"NCT05340530","phase":"PHASE1","title":"To Evaluate the Pharmacokinetic Effects of TQD3606 for Injection in Healthy Adult Subjects","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-04","conditions":"Infections","enrollment":56},{"nctId":"NCT03577938","phase":"NA","title":"Study on the Optimal Strategy for Acute-on-chronic Liver Failure With Integrative Treatment","status":"COMPLETED","sponsor":"Beijing 302 Hospital","startDate":"2019-01-10","conditions":"Acute on Chronic Liver Failure, Traditional Chinese Medicine, Hepatitis B","enrollment":516},{"nctId":"NCT04238091","phase":"PHASE2","title":"Clinical Trial to Evaluate the Efficacy of Fecal Microbiota Transplantation in Patients With Alopecia Areata","status":"WITHDRAWN","sponsor":"Lindsey Bordone","startDate":"2019-12-19","conditions":"Alopecia Areata, Alopecia Totalis, Alopecia Universalis","enrollment":""},{"nctId":"NCT03450187","phase":"PHASE1","title":"A Phase 1 TP-271 Oral PK Multiple Ascending Dose Study","status":"COMPLETED","sponsor":"Tetraphase Pharmaceuticals, Inc","startDate":"2018-03-20","conditions":"Bacterial Infections","enrollment":40},{"nctId":"NCT03234738","phase":"PHASE1","title":"A Phase 1 Safety and PK Study of IV TP-271","status":"COMPLETED","sponsor":"Tetraphase Pharmaceuticals, Inc","startDate":"2017-08-16","conditions":"Bacterial Infections","enrollment":40},{"nctId":"NCT04117607","phase":"PHASE1","title":"Safety and Pharmacokinetics of Rezafungin","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-04","conditions":"Fungal Infection","enrollment":14},{"nctId":"NCT04475588","phase":"PHASE2","title":"Efficacy and Safety of Itolizumab in COVID-19 Complications","status":"COMPLETED","sponsor":"Biocon Limited","startDate":"2020-05-01","conditions":"Acute Respiratory Distress Syndrome, Cytokine Release Syndrome, Covid19","enrollment":32},{"nctId":"NCT01479283","phase":"PHASE3","title":"Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY)","status":"COMPLETED","sponsor":"McMaster University","startDate":"2013-01","conditions":"Infection, Bone Neoplasms","enrollment":602},{"nctId":"NCT02250859","phase":"PHASE1","title":"A Pharmacokinetic Study of Minocycline in Male and Female Volunteers","status":"COMPLETED","sponsor":"Vyne Therapeutics Inc.","startDate":"2014-09","conditions":"Acne","enrollment":12},{"nctId":"NCT04412291","phase":"PHASE2","title":"A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study","status":"UNKNOWN","sponsor":"Karolinska University Hospital","startDate":"2020-06-11","conditions":"Covid-19","enrollment":120},{"nctId":"NCT02765217","phase":"PHASE4","title":"Effect of Lactobacillus Reuteri DSM 17938 to Prevent Antibiotic-associated Diarrhea in Children","status":"COMPLETED","sponsor":"Eskisehir Osmangazi University","startDate":"2017-06-01","conditions":"Antibiotic Associated Diarrhea","enrollment":1325},{"nctId":"NCT01949103","phase":"PHASE1","title":"TD-1607 MAD Study in Healthy Subjects","status":"COMPLETED","sponsor":"Theravance Biopharma","startDate":"2013-10","conditions":"Infections, Bacterial Infections","enrollment":48},{"nctId":"NCT03697993","phase":"PHASE4","title":"Safety and Efficacy Study of Oral Fosfomycin Versus Oral Levofloxacin to Treat Complicated Urinary Syndromes (FOCUS)","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-11-07","conditions":"Urinary Tract Infection","enrollment":62},{"nctId":"NCT01232595","phase":"PHASE2","title":"Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-10","conditions":"Moderate Clostridium Difficile Infection","enrollment":109},{"nctId":"NCT02790996","phase":"PHASE2","title":"Neonatal Vancomycin Trial","status":"TERMINATED","sponsor":"PENTA Foundation","startDate":"2017-02-27","conditions":"Late Onset Neonatal Sepsis","enrollment":242},{"nctId":"NCT04171388","phase":"PHASE4","title":"Enhancing Nutrition and Antenatal Infection Treatment for Maternal and Child Health in Ethiopia","status":"WITHDRAWN","sponsor":"Brigham and Women's Hospital","startDate":"2020-03-01","conditions":"Low Birthweight, Preterm Birth, Maternal; Malnutrition, Affecting Fetus","enrollment":""},{"nctId":"NCT04150224","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics and Food Effects Study of PBTZ169","status":"COMPLETED","sponsor":"Nearmedic Plus LLC","startDate":"2018-07-03","conditions":"Healthy Subjects","enrollment":60},{"nctId":"NCT03723746","phase":"PHASE1","title":"A Study to Evaluate the Safety and Tolerability of JNJ-67670187 in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-10-25","conditions":"Healthy","enrollment":74},{"nctId":"NCT02569541","phase":"PHASE2, PHASE3","title":"Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections","status":"COMPLETED","sponsor":"Arrevus Inc.","startDate":"2015-12","conditions":"Refractory Bone or Joint Infections","enrollment":30},{"nctId":"NCT03162250","phase":"PHASE1","title":"Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2017-07-13","conditions":"Bacteremia","enrollment":27}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":27,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ARM 2: Multi-Dose Antibiotic Prophylaxis"],"phase":"marketed","status":"active","brandName":"Multi-Dose Antibiotic","genericName":"Multi-Dose Antibiotic","companyName":"The Cleveland Clinic","companyId":"the-cleveland-clinic","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A multi-dose antibiotic formulation that delivers multiple antimicrobial agents to treat bacterial infections. Used for Bacterial infections (specific indications unknown without product specification).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}